Asarina is looking to bring a new family of safe, natural, effective compounds (GAMSAs) to market for the treatment of a wide range of stress- and compulsion-related conditions.
Asarina is a Swedish biotech company developing Sepranolone for allopregnanolone-induced stress- and compulsivity-driven disorders. Its product pipeline is built on over 40 years of research into allopregnanolone-related neurological disorders. With a new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists), it is aiming to deliver a new generation of safe, efficacious drugs for neurological conditions ranging from Tourette syndrome to Obsessive Compulsive Disorder that still lack safe, efficacious pharmaceutical treatment


Peter Nordkild
Sub segment
Copenhagen, Denmark

Related companies